Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lessened its stake in Inari Medical, Inc. (NASDAQ:NARI) by 4.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,123,602 shares of the company’s stock after selling 47,878 shares during the quarter. JPMorgan Chase & Co. owned 1.92% of Inari Medical worth $46,337,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in Inari Medical by 67.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock valued at $49,000 after acquiring an additional 473 shares in the last quarter. KBC Group NV raised its holdings in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after buying an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. lifted its position in Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after buying an additional 522 shares during the last quarter. Covestor Ltd boosted its position in shares of Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after purchasing an additional 926 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Inari Medical during the second quarter worth $104,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Insider Transactions at Inari Medical

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the transaction, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This trade represents a 0.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William Hoffman sold 60,000 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $51.16, for a total value of $3,069,600.00. Following the completion of the sale, the director now directly owns 501,233 shares of the company’s stock, valued at $25,643,080.28. The trade was a 10.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 206,000 shares of company stock worth $10,527,870 over the last quarter. 10.60% of the stock is currently owned by insiders.

Inari Medical Trading Down 3.9 %

NASDAQ:NARI opened at $49.77 on Monday. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $65.94. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of -36.87 and a beta of 0.97. The company’s 50-day moving average is $51.80 and its two-hundred day moving average is $48.56.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NARI. Piper Sandler lifted their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, October 29th. Truist Financial raised their price target on Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Canaccord Genuity Group upped their price objective on Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Finally, Stifel Nicolaus began coverage on Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Inari Medical has an average rating of “Moderate Buy” and a consensus target price of $61.80.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.